Reagents for MPXV Assay DevelopmentInquiry Basket
Loading ......
Monkeypox virus was first identified by Preben von Magnus in Copenhagen, Denmark, in 1958 in crab-eating macaque monkeys (Macaca fascicularis) being used as laboratory animals. The virus was originally given the name monkeypox virus because it had been isolated from monkeys; subsequent research reveals that monkeys are not the main host. Other small mammals in the tropical forests of Central and West Africa. are suspected to form a natural reservoir. Monkeypox is a zoonotic virus that transmits from animal to human and vice versa. The virus belongs to the orthopoxvirus genus and the Poxviridae family with a dsDNA genome. The viral family is among the most diverse but also geographically distributed viral families [1].
There are 2 distinct phylogenetic clades of monkeypox viruses: those that exist in West Africa and those in Central Africa. There are very few documented cases of West African monkeypox. Generally, West African monkeypox infections exhibit a less severe illness in humans and nonhuman primates.
Genome comparisons of West and Central African strains yielded a set of candidate genes that may be involved in the differentiating clade virulence. These open reading frames are predicted to be involved in alterations to the viral life cycle, host range, or immune evasion, or are virulence factors. Central African monkeypox prevents T-cell receptor–mediated T-cell activation, prohibiting inflammatory cytokine production in human cells derived from previously infected monkeypox patients. These results suggest that monkeypox may produce a modulator that suppresses host T-cell responses.
The monkeypox virus inhibitor of complement enzymes, a gene that inhibits complement enzymes and is absent in West African strains, has been implicated as an important immune-modulating factor contributing to the increased virulence of Central African strains. Additionally, Central African monkeypox strains selectively downregulate host responses compared to West African strains, specifically apoptosis in the host. Multiple loci may be involved in the observed pathogenicity differences. Furthermore, transcriptional studies have shown that Central African monkeypox appears to selectively silence transcription of genes involved in host immunity during an infection. Determining the range of effects produced with these different viruses will require a multifaceted effort [2].
The orthopox genus of the Poxviridae family contains the enormous, double-stranded DNA virus known as the monkeypox virus [3]. These viruses have a 200 kb genome, with highly conserved genes for replication and assembly machinery in the middle and more variable genes for pathogenicity and host range determination in the terminal ends [4]. As per MPXV's morphology, which is similar to that of other OPXVs, virions are ovoid or brick-shaped particles encased in a geometrically corrugated lipoprotein outer membrane. The outer membrane protects the double-stranded DNA genome and transcription factors. The core's biconcave shape and the presence of lateral entities on both sides are described as fixation artifacts from electron imaging. Despite being a DNA virus, MPXV completes its whole life cycle in the cytoplasm of infected cells. All of the proteins required for viral DNA replication, transcription, virion assembly, and emigration are encoded by the MPXV genome [3]. (Figure 1)
Figure1 Structure and protein composition of MPXV
MPXV belongs to orthopoxvirus family, and its mechanism is similar to that of poxviruses. The pox virus replicates within the cytoplasm, and the process begins with the virus attaching to the cell surface of mammalian cells. The virus is divided into two parts: internal mature virus (IMV) and extracellular enveloped virus (EEV) [5]. With the help of RNA polymerase, which generates viral mRNA under the direction of viral early promoters, virus core material is released into the cytoplasm, initiating the initial cascade of gene expression. Then, in the second step, core uncoating takes place, unknown host and viral mechanisms cause the core structure to dissolve. The uncoating of the virus core structure leads to the entry of viral DNA into the cytoplasm, which produces early and late DNA transcription processes and serves as a template for DNA replication. The subsequent intermediate and late transcription steps necessitate coordination with transcription factors produced from the host, which increases the effectiveness of viral gene expression. IMV, an infectious virus produced by the accumulation of late viral genes, travels through microtubule-mediated trafficking and wraps in the golgi-derived membrane to produce IEV. The cell-associated enveloped virus (CEV), which is formed when the IEV formed fuses with the cell membrane and loses one of its outer membrane wrappings is either directed towards neighboring cells by actin tail polymerization or released directly as free EEV particles. While the IMV form is expected to contribute to virus transmission only after late-stage cell death and membrane rupture, the CEV and EEV forms are thought to be particularly important for rapid cell–cell propagation in vivo. (Figure 2) [6, 7]
Figure 2. Pathophysiology of monkeypox virus, brieffy, the monkeypox virus multiplies within the host and compromises immunity against infections.
It has been shown that smallpox vaccination provides 85% pre-immunization against MPOX infection. There have been hints since the 1960s that immunological responses unique to the vaccine may protect MPOX. Vaccination with Dryvax (Wyeth Laboratories, PA, USA) or another first-generation smallpox vaccine offered complete protection against illness in almost all vaccinated animals in three experiments, including chimpanzees, rhesus macaques, and cynomolgus macaques. The only exception was an unusual animal that failed to produce a take. There are two confirmed accessible to prevent smallpox in the USA, such as ACAM2000 and JYNNEOS. Smallpox vaccinations show an effective defense that may be used to reduce the prevalence of monkeypox. The replication-competent, second-generation vaccinations, however, are not allowed since smallpox vaccines have side effects [8,9].
Traditional vaccine
A live, attenuated, cell-cultured smallpox vaccine called LC16m8 was developed in Japan to replace first-generation vaccines like the Lister and Dryvax strains, which have rare but severe side effects. Both immunogenicity and efficacy were on par with first-generation vaccinations. Because of its decreased virulence and replication competence, LC16m8 is a promising vaccine. A single LC16m8 vaccine protects NHPs against MPOX infection. Post-exposure vaccination with LC16m8 for MPOX-infected NHPs improved clinical manifestation, but all naïve individuals were practically deadly. LC16m8 vaccination 7 days before the MPOX challenge protected NHPs against MPOX. This vaccine has been utilized mainly in Japan [9,10].
ACAM2000, a second-generation vaccination with a higher level of safety than first-generation vaccines, is likewise based on live VARV. When given within three days of contact, smallpox vaccination post-exposure prevention is thought to be 80–93% effective in preventing VARV infection. However, its efficiency quickly dwindles following the onset of smallpox clinical signs. ACAM2000 adverse events comprise fundamental symptoms, including fever, malaise, headache, muscle pain, and adenopathy. Acute adverse events are infrequent but may happen [11,12].
JYNNEOS, a more recent vaccination that also goes by the names Imvamune and Imvanex, gives protection against OPXV and may be administered to immunocompromised people without risk. The JYNNEOS (Imvamune or Imvanex) smallpox/MPOX vaccine is created using attenuated live VACV and cannot cause smallpox, MPOX, or any other infectious illness. Third-generation smallpox vaccine IMVAMUNE has undergone testing in HIV-positive and atopic dermatitis-prone individuals. Furthermore, various research using animal models have shown that protection against MPOX is also possible [13].
Novel vaccine
Every vaccination works on the fundamental tenet that the vaccine may trigger an immune response faster than the pathogen. Even though traditional immunizations gave animals the ability to create powerful neutralizing and preservative Abs, these vaccines are allergenic, expensive, and time-consuming. They suggest the in vitro growth of harmful viruses, raising serious safety concerns. Therefore, a safe and efficient vaccine should be produced to inhibit MPOX. Unlike conventional vaccinations, novel vaccine generation is highly secure and affordable. New vaccine methods against MPOX include virus-like particles (VLPs), recombinant protein, nucleic acid, and nanoparticle-based vaccines. (Table 1) [9]
Table 1 Novel MPOX vaccines in the development phase.
| Vaccine platform | Description of the vaccine composition | Type of the study and Vaccine groups | Results |
| Protein subunit vaccine | Combining the adjuvants Alhydrogel and CpG with the purified protein ectodomains of A33 and B5 derived from EV and L1 and A27 derived from MV. | Animal study: Cynomolgus macaques | An adjuvanted protein-based subunit vaccination administered twice defended NHP against a fatal MPOX challenge. Additionally, it might be utilized to immunize those who reject VACV and to establish baseline protection against the poxvirus safely. |
| Protein subunit vaccine | 10 epitopes (9-mer) containing 147 amino acid residues, the PADRE sequence, the CTxB adjuvant, and the necessary peptide linker. The adjuvant and the EAAAK peptide linker are incorporated into the vaccine's N-terminal end. The PADRE sequence, which serves as a helper T cell epitope for triggering the CTL response in response to various antigens, was also connected to the EAAAK linker. | In silico study | The MPOX epitopic vaccine design has shown excellently defined features regarding antigenicity, non-allergenicity, and physicochemical properties. The vaccine was produced using whole-genome-encoded proteins. Researchers might thus conclude that the vaccine architecture they created is not only optimal but also efficient and secure to administer against MPOX. |
| Protein subunit vaccine | In a multi-epitope vaccination, the epitopes were linked by "GPGPG" linkers and to the adjuvant for cholera toxin B by another EAAAK linker. | Immunoinformatic and molecular docking studies | The modeling of the immune system revealed that the vaccination component stimulated more robust responses from both B and T cells. To induce an immune response against MPOX, a novel risk-free and nearly symptom-free multi-epitope vaccination has been developed that target explicitly three potentially antigenic extracellular proteins. |
| Protein subunit vaccine | MHC-I, MHC-II, and B-cell epitopes | In silico study | A specific immune response to the MPOX was discovered to be elicited by the vaccination, according to immunological simulation studies. The dynamic molecular investigation, which concludes, demonstrates that the vaccine is stable with a minimum RMSF against the MHC-I allele. Studies concluded that one of the main proteins implicated in the pathogenesis of MPOX is the cell surface-binding protein. |
| Virus-like particle | Norovirus shell and protrusion (S&P) VLP platform. | Developing | In this new endeavor, BWV will try to present MPOX antigens within the S&P platform to potentially develop a vaccine candidate that can shield people from MPOX infection. |
| DNA vaccine | Plasmid DNA encoding the MPOX orthologs of the VACV L1R, A27L, A33R, and B5R proteins | Animal study: Rhesus macaques | In one study, individuals immunized with DNA and boosted with proteins had minor illnesses with no lesions or fewer lesions that went away in a matter of days. Th responses and binding Ab titers to all four proteins were induced by DNA/protein vaccination, and these responses were adversely linked with the overall number of lesions. Only a few numbers of linear B cell epitopes that are highly conserved across OPXVs were identified by the sera of the inoculated macaques. |
| DNA vaccine | A27, F9, H3, and L1 are the MV-neutralizing Ab targets in the plasmid cocktail. Researchers also incorporated the EV antigens A33, A56, and B5. In an MPOX challenge model, the core antigen A4 was also used to increase the impact of cytotoxic T lymphocytes. | Animal study: Cynomolgus macaques | These findings show a considerable increase in the DNA vaccine platform's effectiveness, producing immune responses that resemble those of live viral infections. They are considered relevant for developing vaccines against difficult-to-treat human and animal illnesses. |
| mRNA vaccine | Unmodified mRNA that encodes three mAbs, c8A, c6C, and c7D11. | Animal study: rabbits | When the three LNP-formulated mRNA constructs encoding the three different Abs were injected together, the resulting blood levels were almost equal to those obtained when each construct was treated separately. Based on the experimentally established target serum level and the observed decay rate, the Ab levels achieved were not expected to offer protection. |
Resources must be gathered to stop the worldwide spread of MPOX, a disease that is now relevant and concerning globally. mRNA-based LNP induces more neutralizing Abs, more effective MPOX-specific T-cell responses, and protection against MPOX than traditional vaccine methods. Considering that the safety profiles of LNPs relate to dose and combination and that long-time side effects, particularly following numerous dose use, cannot be seriously forecasted as data on long-time health results is clearly not accessible yet. More advanced studies should re-assess the disadvantages and advantages ratio before a continuing comprehensive utilization of mRNA vaccines in low-risk individuals considered for life-threatening periods. In addition, to recognize the most efficient vaccine between traditional and novel vaccines, it is crucial to assess efficiency, including reactogenicity, cytotoxicity test, safety, and adverse effects, especially for high-risk and vulnerable patients. It is necessary to control and contain the MPOX using the lessons learned from the COVID-19 pandemic.
References
| Cat. No. | Product Name | Host | Isotype | Application | |
| CABT-CS828 | Anti-MPXV A29L Monoclonal Antibody, Clone C5 | Human | IgG | ELISA (Cap) | Inquiry |
| CABT-CS829 | Anti-MPXV A29L Monoclonal Antibody, Clone C7 | Human | IgG | ELISA (Det) | Inquiry |
| CABT-CS831 | Anti-MPXV A29L Monoclonal Antibody, Clone 60 | Human | IgG | ELISA | Inquiry |
| CABT-CS683 | Anti-MPXV A29L Monoclonal Antibody, Clone U22 | Human | IgG | ELISA | Inquiry |
| CABT-CS684 | Anti-MPXV A29L Monoclonal Antibody, Clone U22 | Human | IgM | ELISA | Inquiry |
| CABT-CS619 | Anti-MPXV Monoclonal antibody, clone 6D8 | Human | IgG1 | ELSIA, IF | Inquiry |
| CABT-CS621 | Anti-MPXV Monoclonal antibody, clone 6D8 | Human | IgM | ELSIA, IF | Inquiry |
| CABT-CS622 | Anti-MPXV Monoclonal antibody, clone 6D8 | Rabbit | IgG1 | ELSIA, IF | Inquiry |
| CABT-CS618 | Anti-MPXV Monoclonal antibody, clone 6D8 | Mouse | IgG1 | ELSIA, IF | Inquiry |
| Cat. No. | Product Name | Target | Isotype | Application | |
| CABT-NS1653 | Anti-MPXV M1R Monoclonal Antibody, Clone 3133U24 | Human | IgM | ELISA, Control | Inquiry |
| CABT-NS1654 | Anti-MPXV M1R Monoclonal Antibody, Clone 3133U25 | Human | IgG | ELISA, Control | Inquiry |
| CABT-NS1656 | Anti-MPXV A35L Monoclonal Antibody, Clone 3133U27 | Human | IgG | ELISA, Control | Inquiry |
| CABT-NS1655 | Anti-MPXV A35L Monoclonal Antibody, Clone 3133U26 | Human | IgM | ELISA, Control | Inquiry |
| Cat. No. | Product Name | Species Reactivity | Sample | |
| DEIABZ004 | Human Anti-MPXV IgG (Anti-Monkeypox Virus IgG) ELISA Kit | Human | Serum, plasma and other biological fluids | Inquiry |
| DEIABZ005 | Human Anti-MPXV IgM (Anti-Monkeypox Virus IgM) ELISA Kit | Human | Serum, plasma and other biological fluids | Inquiry |
| DEIA-NS2311-2 | Monkeypox Virus (MPXV) H3L Antigen ELISA Kit | Human | Plasma, Serum | Inquiry |
| DEIA-NS2311-3 | Monkeypox Virus (MPXV) A35R Antigen ELISA Kit | Human | Plasma, Serum | Inquiry |
Loading ......
